AbbVie to Present at the Jefferies 2017 London Healthcare Conference
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +9.7%
Join SI Premium – FREE
NORTH CHICAGO, Ill., Nov. 3, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017. Bill Chase, executive vice president and chief financial officer, will present at 3:20 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

View original content with multimedia:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-jefferies-2017-london-healthcare-conference-300549153.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 2.7% Yield
- Building Global Trust in the AI Search Era: DigiMentumPR Explores the Future of PR for Technology Brands
- AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share